The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

banner

Prima's CVac Patent Application Receives US Notice of Allowance

27-May-2014 | Source : AG-IP News | Visits : 3614

SYDNEY - Prima BioMed Ltd announced in a press release that the Company has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for Patent Application 11/561,204 “Compositions for immunotherapy and uses thereof” which protects its CVac™ technology; currently in development for ovarian and pancreatic cancer.

This application protects the method of composition and method of use of Prima’s CVac for the generation of a cytotoxic T cell response against the mucin 1 antigen. CVac is a personalised immunotherapy composed of patients’ own dendritic cells pulsed with the cancer antigen mucin 1, conjugated to oxidised mannan fusion protein. The pulsed dendritic cells are then reinjected into the patient to stimulate an immune response to the mucin 1 cancer antigen.

share



Related Articles